INSTITUTO VALENCIANO DE ONCOLOGIA

Their core work

The Instituto Valenciano de Oncología (IVO) is a dedicated cancer research and treatment center in Valencia, Spain, combining clinical oncology practice with translational research. In EU projects, they contribute domain expertise in tumor biology, cancer immunology, and diagnostic innovation — bridging laboratory findings with patient-facing clinical context. Their H2020 work spans early cancer detection via biosensing and, more recently, fundamental cancer immunotherapy research targeting the mechanisms of allogenic immune responses. They function as a specialist clinical-scientific partner, providing oncological know-how and likely patient cohort access that pure technology organizations cannot offer.

What they specialise in

How they've shifted over time

In their first H2020 project (2015-2018), IVO participated in SAPHELY, a technology-driven initiative focused on photonic biosensors for microRNA-based early disease detection — a diagnostics and medical devices context. Their second project, ULISES (2020-2024), marks a significant pivot toward fundamental cancer immunology: immunological incompatibility, allogenic immune responses, and genetic cargo delivery using plasmids and nanoparticles. The trajectory is a shift from diagnostic instrumentation toward therapeutic mechanism research, moving closer to immunotherapy and gene therapy paradigms.

IVO is moving deeper into cancer immunology and therapeutic research, making them a relevant partner for consortia working on immunotherapy, cancer vaccines, or nucleic acid delivery systems.

How they like to work

IVO has participated exclusively as a consortium partner across both H2020 projects, never taking the coordinator role — consistent with a clinical research institute that contributes specialist oncological expertise rather than project management leadership. With 19 unique partners across 9 countries from just 2 projects, they operate in mid-to-large consortia with diverse international composition. This suggests they are sought out as a domain-specific node rather than a repeat collaborator with a fixed inner circle.

IVO has built connections with 19 distinct consortium partners across 9 countries through only 2 projects, indicating broad and diverse European reach relative to their project volume. No geographic concentration is apparent from the data, though Spanish and broader Southern/Western European partners are likely given their location.

What sets them apart

IVO occupies a rare niche as a standalone cancer-focused research institute (not a university hospital or pharma spin-off) with direct clinical oncology grounding and active participation in both diagnostics and immunotherapy research. For consortium builders, they offer what general biomedical universities cannot: focused oncological expertise, likely access to patient data or tumor sample collections, and a track record in both the diagnostic and therapeutic sides of cancer research. Their bilingual Spanish-European identity and Valencia location also positions them well for Mediterranean and Southern European partnership networks.

Highlights from their portfolio

• ULISES
  The largest-funded project (EUR 389,792) and scientifically the most ambitious — exploring whether immunological incompatibility between individuals can be harnessed to cure cancer and develop vaccines, a frontier area of cancer immunotherapy.
• SAPHELY
  Demonstrates IVO's range beyond pure biology into medical technology, having participated in a photonic biosensor platform for microRNA-based early diagnosis — bridging oncology with digital health instrumentation.